This activity is for healthcare professionals outside of the UK.

This activity is funded by an independent medical education grant from AstraZeneca.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

Decline

Take CE/CME Test
Take CE/CME Test
Prostate Cancer CE/CME ACCREDITED Watch Time: 36 mins

touchMDT PARP inhibitors for metastatic castration-resistant prostate cancer: Enhancing patient–practitioner conversations

A multidisciplinary team and a patient advocate discuss use of PARP inhibitors in mCRPC

 Overview & Learning Objectives
Patient with metastatic castration-resistant prostate cancer
  • Unlocking the data on PARPi to support shared decision-making
    Medical Oncologist and Nurse Practitioner
    Play Arrow Watch Video

    Watch a medical oncologist and a nurse practitioner discuss the data supporting use of PARP inhibitors in mCRPC and how these data can be explained to patients to inform treatment decision-making

    Time: 12:11
    Dr Morgans, Dr Cullen
    Play Arrow Watch Video
  • Understanding precision medicine to guide PARPi use
    Medical Oncologist, Pathologist and Nurse Practitioner
    Play Arrow Watch Video

    Watch a medical oncologist, a pathologist and a nurse practitioner discuss the role of biomarkers to guide use of PARP inhibitors in mCRPC and how biomarker test results can be explained to patients

    Time: 12:11
    Dr Morgans, Prof. Stenzinger, Dr Cullen
    Play Arrow Watch Video
  • Recognizing the importance of patient engagement in PARPi use
    Medical Oncologist, Nurse Practitioner and Patient Advocate
    Play Arrow Watch Video

    Watch a medical oncologist, a nurse practitioner and a patient advocate discuss the importance of engaging patients and hear insights from the perspective of a patient advocate in relation to PARP inhibitor use

    Time: 11:51
    Dr Morgans, Dr Cullen, Mr Collier
    Play Arrow Watch Video

Expert Spotlight

Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, MA, USA
Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, MI, USA
Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

The major reason patients do not receive all possible lines of therapy in mCRPC is:

Submit your answer to see the results

Concerns about treatment toxicity
   
Insufficient use of genetic testing
   
Patient comorbidities
   
Patient refusal
   
Medical Oncologist and Nurse Practitioner
Get the Audio Version
Unlocking the data on PARPi to support shared decision-making
Time: 12:11
Dr Morgans, Dr Cullen

Watch a medical oncologist and a nurse practitioner discuss the data supporting use of PARP inhibitors in mCRPC and how these data can be explained to patients to inform treatment decision-making

Watch Next
Medical Oncologist, Pathologist and Nurse Practitioner

Understanding precision medicine to guide PARPi use

Watch Now

Expert Spotlight

Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, MA, USA
Prof. Albrecht Stenzinger
University of Heidelberg, Heidelberg, Germany
Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, MI, USA
Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What is the biggest reason for under-utilization of HRR mutation testing in mCRPC?

Submit your answer to see the results

Guidelines are unclear about need for testing all patients with mCRPC
   
Inadequate sample for testing
   
Patients refuse testing
   
Cost
   
Medical Oncologist, Pathologist and Nurse Practitioner
Get the Audio Version
Understanding precision medicine to guide PARPi use
Time: 12:11
Dr Morgans, Prof. Stenzinger, Dr Cullen

Watch a medical oncologist, a pathologist and a nurse practitioner discuss the role of biomarkers to guide use of PARP inhibitors in mCRPC and how biomarker test results can be explained to patients

Watch Next
Medical Oncologist, Nurse Practitioner and Patient Advocate

Recognizing the importance of patient engagement in PARPi use

Watch Now

Expert Spotlight

Dr Alicia Morgans
Dana-Farber Cancer Institute, Boston, MA, USA
Dr Grace Cullen
John D. Dingell VA Medical Center, Detroit, MI, USA
Mr Tony Collier
Tackle Prostate Cancer, London, UK
Get the Audio Version

Tutorial

This icon indicates there is a poll question. Click it when you see it to interact with your peers.

Poll

What is the most important thing for patients to understand about PARP inhibitors?

Submit your answer to see the results

Treatment may be life-prolonging
   
Side effects and how they can be managed
   
Impact of treatment on quality of life
   
How PARP inhibitors work
   
Medical Oncologist, Nurse Practitioner and Patient Advocate
Get the Audio Version
Recognizing the importance of patient engagement in PARPi use
Time: 11:51
Dr Morgans, Dr Cullen, Mr Collier

Watch a medical oncologist, a nurse practitioner and a patient advocate discuss the importance of engaging patients and hear insights from the perspective of a patient advocate in relation to PARP inhibitor use

Watch Next
Medical Oncologist and Nurse Practitioner

Unlocking the data on PARPi to support shared decision-making

Watch Now
Back To Top
Overview & Learning Objectives
Overview

In this activity, a multidisciplinary team, including a medical oncologist, a pathologist and a nurse practitioner, share their insights on the use of PARP inhibitors in metastatic castration-resistant prostate cancer. Plus, a patient advocate shares their insights on the specific concerns and informational needs for patients receiving PARP inhibitors.

This activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

This activity has been designed to meet the educational needs of oncologists, urologists, and oncology nurses involved in the management of patients with mCRPC.

USF Accreditation

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

Faculty

Dr Alicia Morgans discloses: Consultant/advisory fees from AAA, Astellas, AstraZeneca, Bayer, Curium, Exelixis, Janssen, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Telix and Tolmar. Grant/research support fees from AAA, Astellas, Janssen, Lantheus, Novartis and Pfizer.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from Agilent, Aignostics, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda and Thermo Fisher. Grant/research support fees from Bayer, Bristol Myers Squibb, Chugai, Incyte and MSD.

Dr Grace Cullen has no interests/relationships or affiliations to disclose in relation to this activity.

Tony Collier discloses: Speaker fees from AstraZeneca, Bayer and MSD.

Content reviewer

Danielle Walker, DNP, APRN, AGNP-C has no relevant financial relationships to disclose.

Touch Medical Contributors

Annette Wiggins has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact cpdsupport@usf.edu 

Accreditations

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Advanced Practice Providers

Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

Nurses

USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.75 contact hour(s) may be earned by learners who successfully complete this  continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

This activity is awarded 0.75 ANCC pharmacotherapeutic contact hour.

Date of original release: 6 March 2025. Date credits expire: 6 March 2028.

If you have any questions regarding credit please contact cpdsupport@usf.edu.

EBAC® Accreditation

touchIME is an EBAC® accredited provider since 2023.

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 51 minutes of effective education time. 

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 CreditTM. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 CreditTM. 

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA) and a partner member of the International Association of Medical Regulatory Authorities (IAMRA).

Faculty Disclosure Statement / Conflict of Interest Policy

In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Requirements for Successful Completion

Certificates of Completion may be awarded upon successful completion of the post-test and evaluation form. If you have completed one hour or more of effective education through EBAC® accredited CE activities, please contact us at accreditation@touchime.org to receive your EBAC® CE credit certificate. EBAC® grants 1 CE credit for every hour of education completed. 

Date of original release: 6 March 2025. Date credits expire: 6 March 2027.

Time to Complete: 51 minutes

If you have any questions regrading the EBAC® credits, please contact accreditation@touchime.org

Learning Objectives

After watching this activity, participants should be better able to:

  • Use the latest data for PARP inhibitors in mCRPC to inform discussions on treatment plans with patients
  • Choose appropriate biomarker tests to guide PARP inhibitor use in mCRPC
  • Describe the importance of patient engagement in the use of PARP inhibitors for mCRPC and how this can be achieved
Faculty & Disclosures
Dr Alicia Morgans

Dana-Farber Cancer Institute, Boston, MA, USA

Dr Morgans is an associate professor of medicine at Harvard Medical School, a genitourinary medical oncologist and the director of the Survivorship Program at Dana-Farber Cancer Institute. read more

As a clinician and investigator, Dr Morgans has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic and cognitive complications, and her work has been funded by grants from the Prostate Cancer Foundation, the National Comprehensive Cancer Network and the Department of Defense. She leads multiple therapeutic and quality of life focused clinical trials for patients with prostate cancer. She has participated in committees of the American Urologic Association and the cardio-oncology committee of the American Heart Association for the development of advanced and localized prostate cancer treatment guidelines.

Dr Alicia Morgans discloses: Consultant/advisory fees from AAA, Astellas, AstraZeneca, Bayer, Curium, Exelixis, Janssen, Lantheus, Macrogenics, Merck, Novartis, Pfizer, Telix and Tolmar. Grant/research support fees from AAA, Astellas, Janssen, Lantheus, Novartis and Pfizer.
Prof. Albrecht Stenzinger

University of Heidelberg, Heidelberg, Germany

Albrecht Stenzinger is professor of molecular tumour pathology, vice chair of the Institute of Pathology (IPH), as well as the director of the IPH Centre for Molecular Pathology (CMP) and section head for molecular diagnostics and biomarker development at the Institute of Pathology, University Hospital Heidelberg, Germany. read more

Dr Stenzinger holds an MD degree from the University of Giessen, completed his residency and fellowship training in pathology at the Charité University Hospital, Berlin and the University Hospital Heidelberg. He is a board-certified surgical pathologist, molecular pathologist and senior attending. Dr Stenzinger received postdoctoral training at the University of Heidelberg and Massachusetts General Hospital/Harvard Medical School, USA. 

He has broad expertise in molecular pathology as well as molecular diagnostics and works in the field of translational research and genetics of solid tumours.

Prof. Albrecht Stenzinger discloses: Advisory board or panel fees from Agilent, Aignostics, Amgen, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, Illumina, Incyte, Janssen, MSD, Novartis, Pfizer, Qlucore, QuiP, Roche, Sanofi, Seagen, Servier, Takeda and Thermo Fisher. Grant/research support fees from Bayer, Bristol Myers Squibb, Chugai, Incyte and MSD.
Dr Grace Cullen

John D. Dingell VA Medical Center, Detroit, MI, USA

Grace Cullen, DNP, FNP-BC, AOCNP, PMGT-BC, FPCN, is a haematology/oncology and palliative care nurse practitioner at the Detroit VA Medical Center. read more

Dr Cullen is an adjunct clinical instructor for the advance practice programme of the Wayne State University College of Nursing. She is a clinical investigator with a research focus on cancer and end-of-life care. She is a reviewer for the Clinical Investigations Committee of the Detroit VA. 

Dr Cullen has multiple peer-reviewed journal publications and presentations on palliative care and oncology, as well as chapter contributions in various reference textbooks. She also serves as a manuscript reviewer for various peer-reviewed journals. 

She is a recipient of the Outstanding Advance Practice Nurse of the Year and EBP Award from the Metro Detroit Oncology Nursing Society, the DVA Secretary’s Excellence in Nursing Award, the DAISY Award for Extraordinary Nurses, the Excellence in Clinical Research and Exemplary Contribution awards from the Detroit VA, and the Volunteerism Award from the Hospice and Palliative Nurses Association. 

She is a member of the board of directors, co-chair of the Palliative Care SIG, and an abstract reviewer for the Association of VA Hematology and Oncology. She is director-at-large for the Metro Detroit Oncology Nursing Society. She is an item writer for the advance oncology nursing practice certification exam by the Oncology Nursing Credentialing Center. She has led QI initiatives increasing palliative care involvement among veterans with stage III lung cancer and stage IV malignancies, as well as improving prostate germline genetic testing at the Detroit VA.

Dr Grace Cullen has no interests/relationships or affiliations to disclose in relation to this activity.
Mr Tony Collier

Tackle Prostate Cancer, London, UK

Tony is an ambassador, awareness speaker, volunteer and fundraiser for Prostate Cancer UK. He is also a trustee of Tackle Prostate Cancer, who are responsible for supporting all prostate cancer support groups across the UK. read more

Tony was diagnosed with advanced stage prostate cancer in 2017. He had a PSA of 129, Gleason 9 with metastases throughout his skeleton from pelvis to skull.

Tony is a consultant to Bennett Brooks Chartered Accountants, who recently acquired the practice he was managing partner of prior to his illness. He was, until recently, the provost (think unelected mayor) of his home town Altrincham and was awarded a British Empire Medal in the Queen’s 2019 birthday honours, recognising his work in the regeneration of Altrincham and charity fundraising for local charities.

Tony is also an ambassador and regional champion for 5K Your Way, a peer-to-peer support group encouraging those living with and beyond cancer to exercise and part of the Move Against Cancer charity. Prior to his diagnosis, Tony was a good-standard club runner training to take on one of the world’s toughest ultramarathons. He’s completed 20 marathons, including all six World Marathon Majors, and two ultramarathons. He continues to run and achieve things that people without stage IV prostate cancer would struggle to do!

Tony is married to Tracey and has two children and four grandchildren who are a massive part of his post cancer diagnosis life.

Mr Tony Collier discloses: Speaker fees from AstraZeneca, Bayer and MSD.
Downloads

View and download resources from this activity to support your learning and share with colleagues

Download Slides
Download Practice Aid
REGISTER NOW FOR FREE ACCESS TO:
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 9 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
This Activity Is Funded By:

An independent medical education grant from AstraZeneca.

The activity is jointly provided by USF Health and touchIME.

touchIME is an EBAC® accredited provider.

The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgement of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

USF

USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

Date of original release: 6 March 2025. Date credits expire: 6 March 2028

EBAC® 

touchIME is an EBAC® accredited provider since 2023.

In compliance with EBAC® guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

This content is intended for healthcare professionals.

Date of original release: 6 March 2025. Date credits expire: 6 March 2027

CE/CME Test (0.75 Points) Close
CE/CME Test

To obtain the CME credit(s), please complete this post-test. Please complete and click to see your results and continue.
Question 1/5
What was the key finding of the TRITON3 trial, a head-to-head comparison of the PARP inhibitor rucaparib versus docetaxel or a second-generation ARPI in men with mCRPC?

ARPI, androgen receptor pathway inhibitors; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase.
 Correct

In the phase III TRITON3 trial, median progression-free survival in patients receiving rucaparib was 11.2 months versus 6.4 months in the control group (physician’s choice of docetaxel, abiraterone acetate or enzalutamide).

Reference

Fizazi K, et al. N Engl J Med. 2023;388:719–32.

Question 2/5
Your patient is a 72-year-old man with mCRPC who presents with bone metastases. He has progressed on previous therapy with an ARPI and docetaxel. He reports a family history of breast and ovarian cancer. What would you do next for this patient?

ARPI, androgen receptor pathway inhibitors; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase; PET, positron emission tomography.
 Correct

The NCCN guidelines recommend that germline and somatic testing for alterations in HRR genes is performed for all patients with mCRPC.1 ESMO guidelines recommend germline testing for BRCA2 and other DNA damage repair mutations in patients with a family history of cancer and in all patients with mCRPC.2 They recommend somatic testing for HRR genes should be considered for all patients with mCRPC.2

Abbreviations

BRCA, BReast CAncer gene; ESMO, European Society for Medical Oncology; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; NCCN, National Comprehensive Cancer Network.

References

  1. NCCN. Prostate cancer. V1.2025. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 29 January 2025).
  2. Parker C, et al. Ann Oncol. 2020;31:1119–34.
Question 3/5
According to NCCN guidelines, which of the following patients should undergo germline genetic testing?

NCCN, National Comprehensive Cancer Network.
 Correct

The NCCN guidelines recommend germline testing for patients with metastatic, regional (node positive), very high-risk and high-risk localized prostate cancer.

Abbreviations

NCCN, National Comprehensive Cancer Network.

Reference

NCCN. Prostate cancer. V1.2025. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 29 January 2025).

Question 4/5
You would like to perform somatic testing to confirm if your patient with mCRPC has a tumour with an HRR mutation, such as BRCA1/2. Which of the following do you need to obtain for testing?

BRCA, BReast CAncer gene; HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer.
 Correct

Ideally, somatic testing for HRR mutations in mCRPC should be performed on a metastatic tumour biopsy sample.1,2 However, as this may not be safe or feasible, testing of a liquid biopsy (cell free/circulating tumour DNA) offers an alternative option.1,2 As HRR mutations are often germline alterations or occur early in tumorigenesis, analysis of a well-preserved primary tumour sample may be informative.2

Abbreviations

HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer.

References

  1. National Comprehensive Cancer Network. Prostate cancer. V1.2025. Available at: www.nccn.org/professionals/physician_gls/pdf/prostate.pdf (accessed 29 January 2025).
  2. Schostak M, et al. Eur Urol Oncol. 2024;7:344–54.
Question 5/5
Your 72-year-old patient with mCRPC presents for follow-up after recent testing for HRR mutations. Based on this testing and other factors, you believe a PARP inhibitor could be the most appropriate treatment. You've discussed the rationale for this treatment, as well as the goals of therapy, but he is uncertain. What would be your next steps to ensure the patient has all possible information to make a decision?

HRR, homologous recombination repair; mCRPC, metastatic castration-resistant prostate cancer; PARP, poly(ADP-ribose) polymerase.
 Correct

Good patient-centred communication skills, focused on defining and meeting the patient’s specific communication needs, fostering trust and addressing the patient’s cognitive/emotional needs, have been associated with enhanced patient satisfaction and better quality of life.1 It is recommended that patients share their communication preferences with HCPs, as some may prefer written instructions, phone calls or electronic communications.2 Good communication can support patients as they make decisions and participate more actively in their care.1

Abbreviations

HCP, healthcare professional; NIH, National Institute of Health.

References

  1. NIH. Communication in cancer care (PDQ ) health professional version. Available at: www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-hp-pdq (accessed 29 January 2025).
  2. NIH. Communication in cancer care (PDQ) patient version. Available at: www.cancer.gov/about-cancer/coping/adjusting-to-cancer/communication-pdq (accessed 29 January 2025).
Post Test Feedback Close
Step 1: Post CE/CME Test Feedback

Please note this feedback form is compulsory to complete your CE/CME evaluation

* = Mandatory Field

Please complete this short online feedback form.
Please indicate how well each statement met your expectations.
Accreditation Close
Accreditation

Please provide your details so that we can send you your certificate, which will be emailed to the address provided. All fields are required.

* = Mandatory Field
Your Accreditation Close
Your Accreditation

Thank you for your submission. Your certificate has been emailed to you.

Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup